Objectives: To investigate medication changes for older patients admitted to hospital and to explore associations between patient characteristics and polypharmacy.
Results: Of 1220 patients who were recruited for the study, medication records at admission were available for 1216. Mean age was 81.3 years (SD, 6.8 years), and 659 patients (54.2%) were women. For the 1187 patients with complete medication records on admission and discharge, there was a small but statistically significant increase in mean number of regular medications per day between admission and discharge (7.1 v 7.6), while the prevalence of medications such as statins (459 [ Medications can, of course, prolong life and prevent serious morbid events in older people. People aged 80 years and over are at highest risk of cardiovascular events, and the absolute benefits of primary and secondary prevention may be greatest in this group. 7 Medications can also improve quality of life through symptom control and maintenance of function. Individualisation of therapy should underpin prescribing, weighing up the potential benefits and risks of medication with reference to the patient's own goals of care. 8, 9 Hospitalisation presents an opportunity for physicians to undertake such a process and to rationalise prescribing for older people.
We aimed to investigate medication changes for older inpatients and explore patient characteristics associated with polypharmacy.
Methods

Participants and setting
This prospective cohort study included patients aged 70 years or older admitted to general medical units of 11 acute care hospitals in Queensland and Victoria -two small secondary care centres (120-160 beds), two rural hospitals (250-280 beds), four metropolitan teaching facilities (300-450 beds) and three major tertiary referral centres (> 650 beds).
Recruitment took place between July 2005 and May 2010 as part of three cohort studies, described in detail elsewhere. [10] [11] [12] Personal or proxy patient consent was obtained in writing before patients entered the study. Patients were excluded if they were admitted to coronary or intensive care units, received palliative care only, or were transferred out of general medical units within 24 hours of admission to inpatient wards. Recruitment took place on weekdays only.
Measurement tool and outcome measures
The interRAI assessment system for acute care (interRAI AC) 13 was used for data collection. This instrument screens many domains, including cognition, communication, mood, behaviour, activities of daily living (ADL), instrumental activities of daily living (IADL), continence, nutrition, skin condition, falls and medical diagnosis.
14 IADL items represent a higher order of functioning than the basic ADL items and dependence in IADL items is likely to occur before dependence in ADL. The interRAI AC was specifically developed for use in the acute care setting, to support comprehensive geriatric assessment of older inpatients.
14 Trained nurse assessors gathered data about the patient's physical, cognitive and psychosocial functioning in the premorbid period (before the current episode of illness, assessed retrospectively at admission) and at admission (based on observations of patients during their first 24 hours in the ward). All available sources of information, including the patients, carers and the medical, nursing and allied health staff, were utilised to complete the interRAI AC instrument, either directly as verbal reports or indirectly through written entries in hospital records.
There are scales embedded in the interRAI instruments that combine single items belonging to a domain (eg, ADL, IADL and cognition), which are used to describe the presence and extent of deficits in that domain. 15 Here, the short ADL scale, the IADL performance scale and the cognitive performance scale were used as summary measures of functional and cognitive status, with higher scores indicating greater incapacity.
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For all patients, prescribed medications were recorded about 24 hours into their hospital stay and again at discharge from hospital. These lists were reviewed so that medications used for a finite period in hospital to manage acute medical conditions (eg, intravenous antibiotics, diuretics and subcutaneous anticoagulants) were not included in the number of regular prescribed medications. Complementary and as-required medications were also excluded. The Anatomical Therapeutic Chemical classification system codes, plus doses, routes of administration and dosing regimens, were recorded at admission and discharge. Data were entered by pharmacists or pharmacy students and verified by a second pharmacist or a geriatrician. Medications were classified as being for controlling symptoms, prevention or both, based on principles used in palliative care settings, 16, 17 as well as expert opinion and consensus among us (geriatricians, physicians and clinical pharmacologists).
Analysis
Frequency distributions were used to describe the characteristics of the study population. Polypharmacy status was categorised into three groups: non-polypharmacy (0-4 drugs), polypharmacy (5-9 drugs) and hyperpolypharmacy (у 10 drugs).
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Depending on the distribution of the data, non-parametric (KruskalWallis test) or parametric (analysis of variance) methods were used to compare continuous data across the polypharmacy categories. For categorical variables, χ 2 tests were used. For paired data, the paired t-test (continuous data) or the McNemar test (nominal data) was used to examine changes between admission and discharge. A variation of the McNemar test (McNemar-Bowker test of symmetry) was used when there were more than two categories.
To examine whether the factors that were significant in univariate analysis were independently associated with the dependent variable (polypharmacy status measured at the ordinal level), an ordinal regression proportional odds procedure was used. Tests for multicollinearity of the independent variables did not show any violation of the assumptions of the regression model. The proportional odds assumption was met using a test of parallel lines provided by the ordinal regression output. The model was adjusted for age and sex, and the results are reported as odds ratios (ORs).
All proportions were calculated as percentages of patients with available data. Significance was set at P < 0.05. Patients with missing data were excluded from relevant analyses. The findings are reported in accordance with the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement for cohort studies.
19 Analyses were performed using SPSS IBM Version 22 (SPSS Inc). There were significant differences across the polypharmacy categories for several variables (Box 1). The number of medications increased in association with a higher number of comorbidities and a higher prevalence of pain, dyspnoea, and dependence in terms of IADL. In contrast, the number of medications decreased in association with higher prevalence of severe cognitive impairment. There were no significant differences across polypharmacy categories based on dependence in terms of ADL, or presence of fatigue, urinary incontinence, behaviour symptoms, falls or weight loss.
A total of 1173/1216 patients (96.5%) had complete data and were included in the ordinal regression model that was used to identify independent predictors of polypharmacy status from the factors significant in the univariate analysis shown in Box 1. With each additional comorbidity, the odds of being in a higher polypharmacy category on admission increased by 27% (OR, 1.27; 95% CI, 1.20-1.34); patients with pain (OR, 1.31; 95% CI, 1.05-1.64) or dyspnoea (OR, 1.64; 95% CI, 1.30-2.07) or who were dependent in terms of IADL premorbidly (OR, 1.70; 95% CI, 1.20-2.41) were also significantly more likely to be in the higher polypharmacy categories ADL = activities of daily living. IADL = instrumental ADL. * Data are numerator/denominator (%) unless otherwise indicated. † The ADL short-form scale comprises four items (personal hygiene, walking, toilet use and eating); range is 0-16, with higher scores reflecting greater level of dependency. ‡ Premorbid IADL performance is assessed on seven items (meal preparation, ordinary housework, managing finances, managing medications, using the telephone, shopping and transportation); scores on each item range from 0 (independent) to 6 (total dependence), and a score of у 2 on any item indicates IADL dependence. § Includes the presence of one or more of the following: verbal abuse, physical abuse, resisting care, and socially inappropriate or disruptive behaviour. ¶ Loss of у 5% bodyweight in the 30 days before admission or у 10% in the 180 days before admission.  (Box 2). In contrast, compared with those with severe cognitive impairment, those with intact cognition (OR, 3.17; 95% CI, 2.05-4.92) or mild to moderate cognitive impairment (OR, 1.95; 95% CI, 1.22-3.11) were significantly more likely to be in the higher polypharmacy categories.
Patients with complete medication records on admission and discharge (1187/1216 patients [97.6%]) were prescribed a mean (SD) of 7.1 (3.7) regular medications per day on admission and 7.6 (3.8) on discharge (P < 0.001).
There was, however, no significant change in the prevalence of medications such as statins (459 [ changed to a higher polypharmacy category and 112 (9.4%) changed to a lower polypharmacy category, both changes being significant (P < 0.001) (Appendix 2).
There was no significant association with diagnosis-related group category for the 109 patients (9.2%) who were taking < 10 medications at admission but taking 10 or more at discharge. There was no clinically meaningful change in the classification of prescribed medication (symptom control, prevention or both) during the inpatient episode (Box 3). For example, the proportion of purely preventive medications in the hyperpolypharmacy category was 1209/3371 (35.9%) at admission and 1508/4117 (36.6%) at discharge. While there was limited variation in number of prescribed medications according to hospital size, this was not statistically significant.
Discussion
Our study showed that three-quarters of older patients assessed were receiving five or more drugs, and more than one-fifth were receiving 10 or more, on admission to hospital. The mean number of prescribed medications per day remained high at discharge, with no clinically meaningful change in the classification (symptom control, prevention or both) of medications, nor in the prevalence of specific drug classes such as statins, opioid analgesics, antipsychotics and benzodiazepines. This may suggest that active attempts were not made to deprescribe when appropriate. Polypharmacy was significantly associated with comorbidity and with symptoms (notably pain and breathlessness) and with worse performance in IADL.
Our study has some limitations. We acknowledge the possibility of selection bias from several sources, including the requirement that patients have an expected hospital stay of at least 48 hours, the recruitment of participants on weekdays only, and the number of patients who declined to participate in the study. The appropriateness of prescribing at the level of individual patients based on clinical indications and contraindications was not considered, and medication doses were not explored. Medications at admission and discharge were documented from patients' prescription charts alone, rather than by complete medication reconciliation using multiple sources of information (patient interview, letter from general practitioner and dispensing history from pharmacy 20 ). Importantly, the design of our study denied us the opportunity to explore whether comorbidities, which may have triggered prescribing of multiple drugs, were the principal cause of the symptoms and functional impairment observed in association with polypharmacy, or whether the polypharmacy itself may have been responsible for some or most of this illness and disability burden, as has been suggested in other studies.
21
The strengths of the study are its large cohort of patients recruited across secondary and tertiary care settings and the rigorous assessment of patients' functional and cognitive status.
For all patients, the objectives of health care, including pharmacotherapy, can be summarised as ameliorating symptoms, improving function and delaying death. With increasing age, prolonging life often becomes a less feasible therapeutic goal. Older patients themselves prioritise improvements in mobility and functional status over longer survival. 22 In a recent survey, only 3% of community-dwelling older people would take medications for primary prevention of cardiovascular disease if adverse effects were severe enough to affect functioning. 23 Our study found that among patients taking 10 or more drugs, more than one in four of these medications were classified as purely preventive, according to mean numbers of drugs per patient, which may constitute an unnecessary treatment burden if clinical benefits are not realised in the short term. In view of our finding of increased prescribing for those with functional impairment, the values and preferences of this patient group should be explored in qualitative studies.
Where and when the process of detailed medication review should occur has not been established. Community medication reviews by pharmacists are an attractive option and have strong face validity. However, several studies of pharmacist-led medication review have shown no positive effect on clinical outcomes or quality of life.
24 Perhaps only a medication review underpinned by careful consideration of the health status of the patient concerned, including estimation of life expectancy and exploration of individual goals of care, is likely to result in clinically meaningful outcomes. The acute care hospital ward under the care of physicians is a setting in which these complex decisions could be considered and actions initiated in discontinuing inappropriate medications. While time constraints are a challenge, they are outweighed by the accessibility of the patients' full history and investigations, and the ability to monitor for adverse effects of drug withdrawal in those patients with longer hospital stays.
In conclusion, polypharmacy and hyperpolypharmacy are common among older people in general medical wards in Australia, with no significant changes in the number or classification of medications between admission and discharge. Patients who are dependent in terms of IADL are at particular risk of polypharmacy. Whether such prescribing in this patient group enhances quality of life and improves longevity or whether it imposes iatrogenic harm and lowers quality of life needs to be established by carefully designed randomised controlled trials of interventions designed to minimise inappropriate polypharmacy.
